menu
    • menu
    [{"orgOrder":0,"company":"Proteostasis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dirocaftor","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Proteostasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Proteostasis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Proteostasis Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Proteostasis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dirocaftor","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Proteostasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Proteostasis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Proteostasis Therapeutics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Posenacaftor

    Menu

    Posenacaftor

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Proteostasis Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Proteostasis Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dirocaftor,Posenacaftor,Nesolicaftor

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Proteostasis Therapeutics Announces Completion of Scientific Advice Meeting with the Dutch Medicines Evaluatio...

                            Details : Dutch regulatory board supportive of choices program, which may lead toward market authorization for treatment of people with CF Choices protocol receives 'high strategic priority' score from CTN.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 13, 2020

                            Lead Product(s) : Dirocaftor,Posenacaftor,Nesolicaftor

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Proteostasis Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Proteostasis Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dirocaftor,Posenacaftor,Nesolicaftor

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Proteostasis Therapeutics Announces Keystone Symposia Presentation of Organoid Study from More than 300 Adult ...

                            Details : The organoid system is a European Commission-funded global project that has attracted a selected number of drug developers and leading CF experts to create a blueprint for customized CF therapy.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 22, 2020

                            Lead Product(s) : Dirocaftor,Posenacaftor,Nesolicaftor

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth